Menveo Uses

Menveo helps prevent invasive meningococcal diseases such as bacterial meningitis. It works by "tricking" the body into thinking it has been exposed to the actual bacteria, but without the risks of a real infection. Although it is approved for people 2 months to 55 years of age, Menveo is used occasionally "off-label" to people outside of this age range.

What Is Menveo Used For?

Menveo® (meningococcal vaccine) is a vaccine approved to provide protection against invasive meningococcal disease, including bacterial meningitis and bloodstream infections. Bacterial meningitis is a bacterial infection of the fluid surrounding the brain and spinal cord. Menveo provides protection only against meningococcal disease caused by Neisseria meningitidis; it does not provide protection against any other types of bacteria.
Invasive meningococcal diseases are quite serious. Even though they are bacterial infections, antibiotics are not always successful for treating such infections.
For instance, as many as 10 to 15 percent of people treated with antibiotics for bacterial meningitis will die. Of those that survive, 11 to 19 percent have serious and sometimes devastating complications such as loss of an arm or leg, deafness, seizures, strokes, or mental retardation. This is why it is so important to prevent invasive meningococcal diseases.
Menveo is approved for individuals between the ages of 2 months and 55 years. However, the Centers for Disease Control (CDC) does not recommend meningococcal vaccines for all individuals in that age group. Routine vaccination with a meningococcal vaccine such as Menveo is recommended for the following groups:
  • Almost all children and adolescents between 11 and 18 years of age
  • College freshmen living in dormitories
  • Anyone living in or traveling to areas of the world where meningococcal disease is common
  • Anyone with a damaged or removed spleen
  • Laboratory workers who are routinely exposed to N. meningitidis
  • United States military recruits
  • People with a specific immune system disorder known as "terminal complement component deficiency"
  • People who might have been exposed to meningitis during an outbreak.
Recognizing Symptoms of ADHD

Menveo Vaccine Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2020 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.